James J McGough1, Alexandra Sturm2, Jennifer Cowen2, Kelly Tung2, Giulia C Salgari2, Andrew F Leuchter2, Ian A Cook3, Catherine A Sugar4, Sandra K Loo2. 1. Semel Institute for Neuroscience and Human Behavior and the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, CA. Electronic address: jmcgough@mednet.ucla.edu. 2. Semel Institute for Neuroscience and Human Behavior and the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, CA. 3. David Geffen School of Medicine at UCLA, the Henry Samueli School of Engineering and Applied Science at UCLA, and NeuroSigma, Inc., Los Angeles, CA. 4. David Geffen School of Medicine and the Fielding School of Public Health at UCLA, Los Angeles, CA.
Abstract
OBJECTIVE:Trigeminal nerve stimulation (TNS), a minimal-risk noninvasive neuromodulation method, showed potential benefits for attention-deficit/hyperactivity disorder (ADHD) in an unblinded open study. The present blinded sham-controlled trial was conducted to assess the efficacy and safety of TNS for ADHD and potential changes in brain spectral power using resting-state quantitative electroencephalography. METHOD: Sixty-two children 8 to 12 years old, with full-scale IQ of at least 85 and Schedule for Affective Disorders and Schizophrenia-diagnosed ADHD, were randomized to 4 weeks of nightly treatment with active or sham TNS, followed by 1 week without intervention. Assessments included weekly clinician-administered ADHD Rating Scales (ADHD-RS) and Clinical Global Impression (CGI) scales and quantitative electroencephalography at baseline and week 4. RESULTS:ADHD-RS total scores showed significant group-by-time interactions (F1,228 = 8.12, p = .005; week 4 Cohen d = 0.5). CGI-Improvement scores also favored active treatment (χ21,168 = 8.75, p = .003; number needed to treat = 3). Resting-state quantitative electroencephalography showed increased spectral power in the right frontal and frontal midline frequency bands with active TNS. Neither group had clinically meaningful adverse events. CONCLUSION: This study demonstrates TNS efficacy for ADHD in a blinded sham-controlled trial, with estimated treatment effect size similar to non-stimulants. TNS is well tolerated and has minimal risk. Additional research should examine treatment response durability and potential impact on brain development with sustained use. CLINICAL TRIAL REGISTRATION INFORMATION: Trigeminal Nerve Stimulation for ADHD; http://clinicaltrials.gov/; NCT02155608.
RCT Entities:
OBJECTIVE: Trigeminal nerve stimulation (TNS), a minimal-risk noninvasive neuromodulation method, showed potential benefits for attention-deficit/hyperactivity disorder (ADHD) in an unblinded open study. The present blinded sham-controlled trial was conducted to assess the efficacy and safety of TNS for ADHD and potential changes in brain spectral power using resting-state quantitative electroencephalography. METHOD: Sixty-two children 8 to 12 years old, with full-scale IQ of at least 85 and Schedule for Affective Disorders and Schizophrenia-diagnosed ADHD, were randomized to 4 weeks of nightly treatment with active or sham TNS, followed by 1 week without intervention. Assessments included weekly clinician-administered ADHD Rating Scales (ADHD-RS) and Clinical Global Impression (CGI) scales and quantitative electroencephalography at baseline and week 4. RESULTS:ADHD-RS total scores showed significant group-by-time interactions (F1,228 = 8.12, p = .005; week 4 Cohen d = 0.5). CGI-Improvement scores also favored active treatment (χ21,168 = 8.75, p = .003; number needed to treat = 3). Resting-state quantitative electroencephalography showed increased spectral power in the right frontal and frontal midline frequency bands with active TNS. Neither group had clinically meaningful adverse events. CONCLUSION: This study demonstrates TNS efficacy for ADHD in a blinded sham-controlled trial, with estimated treatment effect size similar to non-stimulants. TNS is well tolerated and has minimal risk. Additional research should examine treatment response durability and potential impact on brain development with sustained use. CLINICAL TRIAL REGISTRATION INFORMATION: Trigeminal Nerve Stimulation for ADHD; http://clinicaltrials.gov/; NCT02155608.
Authors: D C Glahn; J Kim; M S Cohen; V P Poutanen; S Therman; S Bava; T G M Van Erp; M Manninen; M Huttunen; J Lönnqvist; C G Standertskjöld-Nordenstam; T D Cannon Journal: Neuroimage Date: 2002-09 Impact factor: 6.556
Authors: Lara M Schrader; Ian A Cook; Patrick R Miller; Eve R Maremont; Christopher M DeGiorgio Journal: Epilepsy Behav Date: 2011-08-04 Impact factor: 2.937
Authors: Kelly Posner; Gregory K Brown; Barbara Stanley; David A Brent; Kseniya V Yershova; Maria A Oquendo; Glenn W Currier; Glenn A Melvin; Laurence Greenhill; Sa Shen; J John Mann Journal: Am J Psychiatry Date: 2011-12 Impact factor: 18.112
Authors: James J Mahoney; Colleen A Hanlon; Patrick J Marshalek; Ali R Rezai; Lothar Krinke Journal: J Neurol Sci Date: 2020-09-20 Impact factor: 3.181
Authors: Mark L Wolraich; Joseph F Hagan; Carla Allan; Eugenia Chan; Dale Davison; Marian Earls; Steven W Evans; Susan K Flinn; Tanya Froehlich; Jennifer Frost; Joseph R Holbrook; Christoph Ulrich Lehmann; Herschel Robert Lessin; Kymika Okechukwu; Karen L Pierce; Jonathan D Winner; William Zurhellen Journal: Pediatrics Date: 2019-10 Impact factor: 7.124
Authors: Mark I Johnson; Carole A Paley; Priscilla G Wittkopf; Matthew R Mulvey; Gareth Jones Journal: Medicina (Kaunas) Date: 2022-06-14 Impact factor: 2.948
Authors: Laura Dubreuil-Vall; Federico Gomez-Bernal; Ana C Villegas; Patricia Cirillo; Craig Surman; Giulio Ruffini; Alik S Widge; Joan A Camprodon Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2020-11-25
Authors: Shannon M Bennett; Jeffrey S Hindin; Justin Mohatt; Christopher Bauer; Jennifer Schild; Avital Falk; Matthew Specht; Douglas Woods; John Walkup Journal: Child Psychiatry Hum Dev Date: 2021-05-06
Authors: Stephen V Faraone; Tobias Banaschewski; David Coghill; Yi Zheng; Joseph Biederman; Mark A Bellgrove; Jeffrey H Newcorn; Martin Gignac; Nouf M Al Saud; Iris Manor; Luis Augusto Rohde; Li Yang; Samuele Cortese; Doron Almagor; Mark A Stein; Turki H Albatti; Haya F Aljoudi; Mohammed M J Alqahtani; Philip Asherson; Lukoye Atwoli; Sven Bölte; Jan K Buitelaar; Cleo L Crunelle; David Daley; Søren Dalsgaard; Manfred Döpfner; Stacey Espinet; Michael Fitzgerald; Barbara Franke; Manfred Gerlach; Jan Haavik; Catharina A Hartman; Cynthia M Hartung; Stephen P Hinshaw; Pieter J Hoekstra; Chris Hollis; Scott H Kollins; J J Sandra Kooij; Jonna Kuntsi; Henrik Larsson; Tingyu Li; Jing Liu; Eugene Merzon; Gregory Mattingly; Paulo Mattos; Suzanne McCarthy; Amori Yee Mikami; Brooke S G Molina; Joel T Nigg; Diane Purper-Ouakil; Olayinka O Omigbodun; Guilherme V Polanczyk; Yehuda Pollak; Alison S Poulton; Ravi Philip Rajkumar; Andrew Reding; Andreas Reif; Katya Rubia; Julia Rucklidge; Marcel Romanos; J Antoni Ramos-Quiroga; Arnt Schellekens; Anouk Scheres; Renata Schoeman; Julie B Schweitzer; Henal Shah; Mary V Solanto; Edmund Sonuga-Barke; César Soutullo; Hans-Christoph Steinhausen; James M Swanson; Anita Thapar; Gail Tripp; Geurt van de Glind; Wim van den Brink; Saskia Van der Oord; Andre Venter; Benedetto Vitiello; Susanne Walitza; Yufeng Wang Journal: Neurosci Biobehav Rev Date: 2021-02-04 Impact factor: 9.052
Authors: Adam D Farmer; Adam Strzelczyk; Alessandra Finisguerra; Alexander V Gourine; Alireza Gharabaghi; Alkomiet Hasan; Andreas M Burger; Andrés M Jaramillo; Ann Mertens; Arshad Majid; Bart Verkuil; Bashar W Badran; Carlos Ventura-Bort; Charly Gaul; Christian Beste; Christopher M Warren; Daniel S Quintana; Dorothea Hämmerer; Elena Freri; Eleni Frangos; Eleonora Tobaldini; Eugenijus Kaniusas; Felix Rosenow; Fioravante Capone; Fivos Panetsos; Gareth L Ackland; Gaurav Kaithwas; Georgia H O'Leary; Hannah Genheimer; Heidi I L Jacobs; Ilse Van Diest; Jean Schoenen; Jessica Redgrave; Jiliang Fang; Jim Deuchars; Jozsef C Széles; Julian F Thayer; Kaushik More; Kristl Vonck; Laura Steenbergen; Lauro C Vianna; Lisa M McTeague; Mareike Ludwig; Maria G Veldhuizen; Marijke De Couck; Marina Casazza; Marius Keute; Marom Bikson; Marta Andreatta; Martina D'Agostini; Mathias Weymar; Matthew Betts; Matthias Prigge; Michael Kaess; Michael Roden; Michelle Thai; Nathaniel M Schuster; Nicola Montano; Niels Hansen; Nils B Kroemer; Peijing Rong; Rico Fischer; Robert H Howland; Roberta Sclocco; Roberta Sellaro; Ronald G Garcia; Sebastian Bauer; Sofiya Gancheva; Stavros Stavrakis; Stefan Kampusch; Susan A Deuchars; Sven Wehner; Sylvain Laborde; Taras Usichenko; Thomas Polak; Tino Zaehle; Uirassu Borges; Vanessa Teckentrup; Vera K Jandackova; Vitaly Napadow; Julian Koenig Journal: Front Hum Neurosci Date: 2021-03-23 Impact factor: 3.169